Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Up 118.8% in November

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 55,800 shares, a growth of 118.8% from the November 15th total of 25,500 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 40,500 shares, the short-interest ratio is currently 1.4 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Friday, November 15th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC increased its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Daré Bioscience Stock Down 0.3 %

Shares of DARE opened at $3.18 on Friday. Daré Bioscience has a 52-week low of $3.05 and a 52-week high of $7.56. The company has a 50-day simple moving average of $3.56 and a 200-day simple moving average of $3.77. The company has a market capitalization of $27.67 million, a PE ratio of -5.38 and a beta of 1.27.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.